<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125528</url>
  </required_header>
  <id_info>
    <org_study_id>A1159</org_study_id>
    <nct_id>NCT00125528</nct_id>
  </id_info>
  <brief_title>D-cycloserine in the Management of Chronic Low Back Pain</brief_title>
  <official_title>D-Cycloserine in the Management of Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas J. Schnitzer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-clinical studies in rats suggest that D-cycloserine (DCS) is effective in the management
      of chronic neuropathic pain. This pilot study will attempt to determine the effect of
      D-cycloserine in the treatment of chronic low back pain. Other aims of this study are to
      determine the safety of D-cycloserine in the treatment of chronic low back pain and to
      determine which pain measurement scales are best at measuring the efficacy of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human brain imaging studies indicate that the medial prefrontal cortex activity can predict
      more than 80% of the variance of chronic back pain intensity. Therefore, the investigators
      have hypothesized that modulation of brain activity at this site should result in analgesia.
      D-cycloserine has been shown to potentiate conditioned fear extinction. Based on this the
      investigators hypothesize that chronic neuropathic pain (back pain with radiculopathy) is
      partially mediated or potentiated by decreased ability to extinguish the pain memory, which
      the investigators hypothesize to be mediated through reward/aversion brain circuitry, and
      specifically through medial prefrontal cortex. They have tested this idea in pre-clinical
      studies and demonstrated that rats with neuropathic pain show analgesia over the long-term
      when treated with D-cycloserine. In humans with chronic back pain, the investigators
      hypothesize that D-cycloserine will enhance extinction of back pain which in turn should
      result in reduced emotional relevance of the pain, that is reduced suffering. It is quite
      possible that the overall intensity of the back pain will be unaffected, however, the
      associated suffering will be significantly attenuated.

      This will be a double-blind, randomized, parallel group escalating dose study comparing
      D-cycloserine twice a day (bid) with placebo bid in patients with chronic low back pain.
      Subjects meeting inclusion criteria will continue baseline medications and be treated for 12
      weeks with study drug: 50 mg bid DCS or matching placebo for the first 4 weeks, then 100mg
      bid DCS or matching placebo for 4 weeks and finally 200mg bid DCS or matching placebo for 4
      weeks. Assessments of efficacy and safety will be undertaken every 2 weeks using standard,
      validated instruments to evaluate change in pain, function, quality of life and adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Numeric Rating Scale (NRS-11)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in NRS score after 6 weeks of treatment as compared to baseline. The numeric rating scale is an 11-point rating scale wherein participants rated their current lower back pain intensity on a scale from 0 to 10, with 0 meaning no pain and 10 being the worst pain possible. Thus, a larger negative number indicates positive change and a higher efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>McGill Pain Questionnaire (MPQ)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in MPQ score after 6 weeks of treatment as compared to baseline. The MPQ score uses a Pain Rating Index from 0 to 20 where 0 is evidence of no pain and 20 indicates the highest pain possible. A lower score is also indicative of a lower quality of pain. Thus, a larger negative number indicates positive change and therefore higher efficacy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-cycloserine 50mg bid/100mg bid/200 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo bid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a history of low back pain for a minimum of 6 months with or without
             radiation of pain to leg or buttocks.

          -  Must be 18 years of age.

          -  Must have a visual analogue scale (VAS) pain score &gt;50 mm

          -  Must be in generally stable health

          -  Must be willing to abstain from drinking alcohol during the course of the study.

          -  If female, must be post-menopausal for at least one year or practicing an accepted,
             highly effective method of contraception or abstinence and plan to continue either
             during the course of the study.

          -  Must be able and willing to read and understand instructions as well as questionnaires

          -  Must sign an informed consent document after complete explanation of the study
             documenting that they understand the purpose of the study, procedures to be
             undertaken, possible benefits, potential risks, and are willing to participate.

        Exclusion Criteria:

          -  Low back pain associated with any systemic signs or symptoms, e.g., fever, chills.

          -  Evidence of rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures,
             fibromyalgia, history of surgery or tumor in the back.

          -  Involvement in litigation regarding their back pain or have a disability claim or are
             receiving workman's compensation or seeking either as a result of their low back pain

          -  Neurologic disorder, including history of seizures

          -  Major psychiatric disorder during the past 6 months

          -  Moderate or severe depression as determined by the Beck Depression Inventory or any
             active suicidal ideation

          -  Significant other medical disease such as unstable diabetes mellitus, congestive heart
             failure, coronary or peripheral vascular disease, chronic obstructive lung disease, or
             malignancy

          -  Significant renal disease or severe renal insufficiency

          -  History of, or current, substance abuse/dependence including alcohol

          -  Significantly abnormal laboratory values

          -  Pregnant or lactating at any time during the course of the study

          -  Known sensitivity to D-cycloserine

          -  Currently taking any of the following medications: ethionamide, dilantin, isoniazid
             (INH), pyridoxine (vitamin B6)

          -  In the judgment of the investigator, unable or unwilling to follow the protocol and
             instructions

          -  Any change in medication for back pain in the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Schnitzer, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vania Apkarian, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117251/pdf/10.1177_1744806916678627.pdf</url>
  </link>
  <results_reference>
    <citation>Schnitzer TJ, Torbey S, Herrmann K, Kaushal G, Yeasted R, Vania Apkarian A. A randomized placebo-controlled pilot study of the efficacy and safety of D-cycloserine in people with chronic back pain. Mol Pain. 2016 Nov 15;12. pii: 1744806916678627. Print 2016.</citation>
    <PMID>27852965</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2005</study_first_submitted>
  <study_first_submitted_qc>July 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>February 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Thomas J. Schnitzer</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>chronic pain</keyword>
  <keyword>low back pain</keyword>
  <keyword>D-cycloserine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D-cycloserine</title>
          <description>D-cycloserine: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: placebo bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-cycloserine</title>
          <description>D-cycloserine: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: placebo bid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.65" spread="11.56"/>
                    <measurement group_id="B2" value="54.76" spread="10.84"/>
                    <measurement group_id="B3" value="54.71" spread="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Numeric Rating Scale (NRS-11)</title>
          <description>Numeric rating scale is an 11-point rating scale wherein participants rated their current lower back pain intensity on a scale from 0 to 10, with 0 meaning no pain and 10 being the worst pain possible. Thus, a lower score represents a better pain state at baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.47" spread="1.40"/>
                    <measurement group_id="B2" value="6.6" spread="1.50"/>
                    <measurement group_id="B3" value="6.54" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Numeric Rating Scale (NRS-11)</title>
        <description>Change in NRS score after 6 weeks of treatment as compared to baseline. The numeric rating scale is an 11-point rating scale wherein participants rated their current lower back pain intensity on a scale from 0 to 10, with 0 meaning no pain and 10 being the worst pain possible. Thus, a larger negative number indicates positive change and a higher efficacy.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>D-cycloserine: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Numeric Rating Scale (NRS-11)</title>
          <description>Change in NRS score after 6 weeks of treatment as compared to baseline. The numeric rating scale is an 11-point rating scale wherein participants rated their current lower back pain intensity on a scale from 0 to 10, with 0 meaning no pain and 10 being the worst pain possible. Thus, a larger negative number indicates positive change and a higher efficacy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="0.50"/>
                    <measurement group_id="O2" value="-1.55" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>McGill Pain Questionnaire (MPQ)</title>
        <description>Change in MPQ score after 6 weeks of treatment as compared to baseline. The MPQ score uses a Pain Rating Index from 0 to 20 where 0 is evidence of no pain and 20 indicates the highest pain possible. A lower score is also indicative of a lower quality of pain. Thus, a larger negative number indicates positive change and therefore higher efficacy.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D-cycloserine</title>
            <description>D-cycloserine: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo bid</description>
          </group>
        </group_list>
        <measure>
          <title>McGill Pain Questionnaire (MPQ)</title>
          <description>Change in MPQ score after 6 weeks of treatment as compared to baseline. The MPQ score uses a Pain Rating Index from 0 to 20 where 0 is evidence of no pain and 20 indicates the highest pain possible. A lower score is also indicative of a lower quality of pain. Thus, a larger negative number indicates positive change and therefore higher efficacy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="0.66"/>
                    <measurement group_id="O2" value="-1.00" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-cycloserine</title>
          <description>D-cycloserine: D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: placebo bid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness/Tingling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Extremity Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It is not clear whether observed effects are due to escalating dose or duration of D-cycloserine use. A larger population and longer duration of treatment would be needed to determine this.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Thomas Schnitzer</name_or_title>
      <organization>Northwestern Universiyt</organization>
      <phone>312-503-2315</phone>
      <email>tjs@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

